- Reviewed by Toni Golen, MD, Editor in Chief, Harvard Women's Health Watch; Editorial Advisory Board Member, Harvard Health Publishing; Contributor
It's nearly impossible to miss the buzz surrounding the newest generation of obesity drugs, whose popularity is soaring alongside reports of jaw-dropping weight loss among people taking them.
Semaglutide — first marketed as Ozempic for diabetes and later as Wegovy for obesity — is heralded as a breakthrough drug for its ability to promote an average loss of 15% to 20% of a person's body weight. But it's becoming apparent that the medications, which include others in its class and mimic a naturally produced hormone called GLP-1, might offer additional benefits, dampening cravings for things other than food.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
About the Author
Maureen Salamon, Executive Editor, Harvard Women's Health Watch
About the Reviewer
Toni Golen, MD, Editor in Chief, Harvard Women's Health Watch; Editorial Advisory Board Member, Harvard Health Publishing; Contributor
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.